Benzoyl Peroxide

drug
On this page

Also known as Acetoxyl 2.5Acetoxyl 5AcnecideAcnecide 10AcnegelAcnegel fteAcnidazilAnhydrous benzoyl peroxideBenoxyl 10Benoxyl 20Benoxyl 5Benzagel 10Benzagel 5BenzamycinBenzoyl peroxide anhydrousBenzoyl peroxide component of acanyaBenzoyl peroxide component of aktipakBenzoyl peroxide component of benzaclinBenzoyl peroxide component of benzamycin

Summary

Benzoyl Peroxide (CHEMBL1200370) is an approved small molecule (ATC D10AE01); indicated across 5 conditions including acne and molluscum contagiosum.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: D10AE01 (+1 more)
  • Indications: 5 conditions
  • Clinical trials: 33
  • Chemistry: 242.23 Da · C14H10O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1200370
NameBenzoyl Peroxide
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID7187
ATCD10AE01, D10AE51
Molecular formulaC14H10O4
Molecular weight242.23
InChIKeyOMPJBNCRMGITSC-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C(=O)OOC(=O)C2=CC=CC=C2

IUPAC name: benzoyl benzenecarboperoxoate

Also known as: Acetoxyl 2.5, Acetoxyl 5, Acnecide, Acnecide 10, Acnegel, Acnegel fte, Acnidazil, Anhydrous benzoyl peroxide, Benoxyl 10, Benoxyl 20, Benoxyl 5, Benzagel 10

Patent coverage: 143,917 distinct patent families (354,767 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Prothrombin.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA8.2Potency6.3nMCHEMBL_ACT_3643999
F25.04AC509020nMCHEMBL_ACT_25196869

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
acne4MONDO:0011438EFO:0003894
molluscum contagiosum3MONDO:0005855EFO:0007375
actinic keratosis2MONDO:0005173EFO:0002496
rosacea1MONDO:0006604EFO:1000760

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 33.

Phase distribution

PhaseTrials
PHASE415
PHASE310
Not specified5
PHASE22
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00658112PHASE4COMPLETEDMeasuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
NCT00887484PHASE4COMPLETEDA Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
NCT00919191PHASE4COMPLETEDEvaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
NCT00926367PHASE4COMPLETEDTwo-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
NCT00964223PHASE4COMPLETEDA Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
NCT00964366PHASE4COMPLETEDStudy to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
NCT01138735PHASE4COMPLETEDEpiduo Pediatric Acne Study
NCT01206348PHASE4COMPLETEDCombination Treatment for Moderate to Severe Acne
NCT01260571PHASE4UNKNOWNClinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)
NCT01448733PHASE4UNKNOWNSafety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris
NCT01613924PHASE4WITHDRAWNEfficacy of Handheld Acne Heat Device
NCT02589405PHASE4COMPLETEDBenzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
NCT04021524PHASE4COMPLETEDBPO vs Hibiclens Soap for Surgical Preparation
NCT04548349PHASE4COMPLETEDProfiling the Skin Microbiome in Response to Altreno in Acne Patients
NCT05676411PHASE4WITHDRAWNBenzoyl Peroxide and Electrocautery Skin Incision to Eradicate Cutibacterium Acnes
NCT00421993PHASE3COMPLETEDA Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
NCT00422240PHASE3COMPLETEDStudy to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
NCT00446043PHASE3COMPLETEDLong-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
NCT00663286PHASE3COMPLETEDA Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
NCT00664248PHASE3COMPLETEDA Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
NCT00869492PHASE3UNKNOWNComparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of Acne
NCT00877409PHASE3UNKNOWNSafety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II
NCT02465632PHASE3COMPLETEDTo Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.
NCT05536882PHASE3WITHDRAWNMC RCT - BPO vs Adapalene
NCT05629468PHASE3COMPLETEDComparing Efficacy of Azithromycin and Probiotics for Treatment of Acne Vulgaris
NCT07032649PHASE2NOT_YET_RECRUITINGEvaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
NCT03257202PHASE2COMPLETEDTopical Treatment and Prevalence of P. Acnes
NCT01428466PHASE1COMPLETEDJapanese Phase 1 Study of GSK2585823
NCT00558831Not specifiedCOMPLETEDStudy of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
NCT00787943Not specifiedCOMPLETEDStudy of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
NCT01052246Not specifiedCOMPLETEDPulsed Dye Laser Treatment of Acne Vulgaris
NCT01176955Not specifiedCOMPLETEDA Novel Method to Improve Acne Outcomes
NCT05355844Not specifiedUNKNOWNCutibacterium Acnes in Deep Tissues in Primary Spine and Shoulder Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).